Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 11/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 11/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.42 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153030 | 1.00 | ITGA4 (0.47) | ITGA4ITGB1ITGB7CHRM4ITGA2 | |
| SCHEMBL6402913 | 1.00 | ITGA4 (0.47) | ITGA4ITGB1ITGB7CHRM4ITGA2 | |
| SCHEMBL6159009 | 0.92 | ITGB1 (0.49) | ITGA4ITGB1ITGB7 | |
| SCHEMBL6147636 | 0.92 | ITGB1 (0.49) | ITGA4ITGB1ITGB7 | |
| SCHEMBL6150353 | 0.92 | ITGB1 (0.49) | ITGA4ITGB1ITGB7 | |
| SCHEMBL6401978 | 0.90 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6149415 | 0.90 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6401982 | 0.90 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6149727 | 0.83 | ITGA4 (0.44) | ITGA4ITGB1ITGB7ITGA2ITGB3 | |
| SCHEMBL6402116 | 0.83 | ITGA4 (0.44) | ITGA4ITGB1ITGB7ITGA2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | claimed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | ITGA4 2/4885ITGB1 4/4885ITGB7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.